Agonism of the CD137 co-stimulatory pathway synergizes with the Listeria monocytogenes-based immunotherapy, axalimogene filolisbac, to promote durable tumor regression in a murine HPV+ tumor model
Immunotherapy: A New Strategy for the Treatment of Cervical Cancer
Tolerability of ADXS11-001 Lm-LLO Listeria Based Immunotherapy With Mitomycin, Fluorouracil and Radiation for Anal Cancer
Advaxis’ Listeria monocytogenes-based immunotherapies rapidly impair intratumoral regulatory T cell survival and function and promote effector T cell recruitment, activation and differentiation
Baseline serum protein levels associated with survival in axalimogene filolisbac (AXAL)-treated metastatic cervical cancer patients: The GOG/NRG-0265 trial
Identification of an intratumoral immune gene signature associated with tumor regression in an axalimogene filolisbac-treated murine HPV+ tumor model
Therapeutic options for treatment of human papillomavirus-associated cancers – novel immunologic vaccines: ADXS11–001
Blood Protein Levels May Predict Cervical Cancer Patients Likely to Benefit from Advaxis’ Immunotherapy
2017 Investor Analyst Day
Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy
High-dose treatment with ADXS11-001, a Listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer
A prospective phase 2 trial (GOG-0265) of the Listeria-based HPV immunotherapy axalimogene filolisbac (AXAL) in second- and third- line metastatic cervical cancer: An NRG Oncology Group trial
HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV-specific T cell immunity (#7632)
ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage 1 [and stage 2] of the phase II GOG/NRG-0265 study
